Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82,85,89,92 and 97

Leukemia

Volumn 24, Issue 2, 2010, Pages 298-308

  Escherich, G ^a   Horstmann, M A ^a,b   Zimmermann, M ^c   Janka Schaub, G E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Research Institute Children's Cancer Center   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Childhood; In vitro drug sensitivity testing; Long term outcome; Minimal residual disease; Second malignancy

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; ARTICLE; B LYMPHOCYTE; BRAIN CANCER; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; GERMANY; HUMAN; IN VITRO STUDY; LEUKOCYTE COUNT; LONG TERM CARE; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SECOND CANCER; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 76749112909     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.249     Document Type: Article

References (32)

1. Janka GE, Winkler K, Jürgens H, Göbel U, for the COALL Study Group. Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose metho-trexate. Haematol Blood Transfus 1987; 30: 456-460.
2. Jürgens H, Janka G, Ibrahim M, Tonert C, Winkler K, Göbel U. Prognostic significance of exposure to intermediate-dose metho-trexate in children with standard risk ALL: the COALL 82/85 experience. Haematol Blood Transf 1992; 34: 338-342.
3. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL), long-term follow up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-2239.
4. Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R. In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Padiatr 1999; 211: 233-238.
5. Harms DO, Göbel U, Spaar HJ, Graubner U, Jorch N, Gutjahr P, et al., for the COALL Study Group. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood 2003; 102: 2736-2740.
6. Escherich G, Göbel U, Jorch N, Spaar HJ, Janka-Schaub GE. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klin Padiatr 2007; 219: 134-138.
7. Janka GE, Göbel U, Gutjahr P, Jürgens H, Spaar HJ, Winkler K, for the COALL Study Group. Possible adverse influence of administering intrathecal methotrexate (it-MTX) non-concurrently with cranial radiotherapy (CRT) in the treatment of childhood acute lymphocytic leukemia (ALL). Med Ped Oncol 1988a; 16: 394.
8. Janka GE, Winkler K, Göbel U, Graubner U, Gutjahr P, Haas RJ, et al., for the COALL Study Group. Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. Leukemia 1988b; 2: 73-78.
9. Janka-Schaub GE, Harms D, Göbel U, Graubner U, Gutjahr P, Haas RJ, et al., for the COALL Study Group. Randomized comparison of rotational chemotherapy in high-risk acute lympho-blastic leukaemia of childhoodFfollow up after 9 years. Eur J Pediatr 1996; 155: 640-648.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
11. Andersen PK, Borch-Johnsen K, Deckert T, Green A, Hougaard P, Keiding N et al. A Cox regression model for the relative mortality and its application to diabetes mellitus survival data. Biometrics 1985; 41: 921-932.
12. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd edn. Wiley Series in Probability and Statistics Wiley: New York, NY, 2002 439pp.
13. Graubner UB, Porzig S, Jorch N, Kolb R, Wessalowski R, Escherich G et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Ped Blood Cancer 2007; 50: 259-263.
14. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738. (Pubitemid 28534955)
15. Conter V, Schrappe M, Arico M, Reiter A, Rizzari M, Dördelmann M et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukaemia with high WBC count and good response to prednisone. J Clin Oncol 1997; 15: 2786-2791.
16. 2 PEG-asparaginase in children with ALL treated according to protocol COALL 06-97. J Ped Blood Cancer 2006; 46: 18-25.
17. Kaatsch P, Reinisch I, Spix C, Berthold F, Janka-Schaub G, Mergenthaler A et al. Case control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. Cancer Causes Control 2009; 20: 965-980.
18. Baker KS, DeFor TE, Burns LJ, Ramsay NKC, Neglia JP, Robinson LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-1358.
19. Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm HJ et al. Secondary neoplasms subsequent to Berlin-Frankfurt-München therapy of acute lymphoblastic leukemia. Blood 2000; 95: 2770-2775.
20. Erb N, Harms D, Janka-Schaub GE. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998; 42: 266-272.
21. Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukemia. Brit J Haematol 2003; 123: 100-102.
22. Broxon EH, Dole M, Wong R, Laya BF, Stork L. Portal hypertension develops in a subset of children with standard risk leukemia treated with oral 6-thioguanine during maintenance therapy. Ped Blood Cancer 2005; 44: 226-231.
23. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-139.
24. Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 2001; 8: 611-614.
25. Pieters R, Huismans DR, Loonen AH, Hahlen K, van der Does-van den Berg A, van Wering ER et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991; 338: 399-403.
26. Kaspers GJ, Pieters R, Van Zantwijk CH, De Laat PA, De Waal FC, Van Wering ER et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991; 64: 469-474.
27. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997; 89: 2959-2965.
28. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 376-385.
29. Styczynski J, Wysocki M. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 2004; 22: 963-964.
30. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.
31. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukaemia. European Organization for research and treatment of CancerF Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
32. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al., International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.